Literature DB >> 8851573

Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies.

B G Reigner1, H A Welker.   

Abstract

A metaanalysis was conducted on data from 172 subjects (healthy volunteers and uninfected patients) included in 10 pharmacokinetic studies of fleroxacin after oral administration. The objectives of this analysis were (i) to estimate the typical values of two key pharmacokinetic parameters, clearance over systemic availability (CL/F) and volume of distribution over systemic availability (V/F), after the administration of therapeutic doses and (ii) to study qualitatively and quantitatively the factors which influence the elimination and distribution of fleroxacin. The main pharmacokinetic parameters, CL/F and V/F, were analyzed separately by a standard two-stage approach. The covariates investigated were predicted creatinine clearance (CLCR), age, gender, body surface area, body weight, and lean body weight (LBW). The predicted CL/F and V/F were 83.5 ml/min and 101 liters, respectively, for a typical male subject (CLCR, 70 ml/min; LBW, 54 kg; age, 54 years). Modeling of CL/F indicated that this parameter increases linearly with CLCR, decreases linearly with age, and is 10.8 ml/min lower in females than in males. The best model for V/F showed a linear increase with LBW and a linear decrease with age. V/F was found to be 20.4 liters greater in males than in females. In conclusion, this metaanalysis has shown that CLCR, age, and gender influence the elimination of fleroxacin from the body, whereas V/F is influenced by LBW, age, and gender.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851573      PMCID: PMC163160     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.

Authors:  A M Taburet; A Devillers; P Thomare; J P Fillastre; P Veyssier; E Singlas
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

2.  Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.

Authors:  E Singlas; A Leroy; E Sultan; M Godin; B Moulin; A M Taburet; M Dhib; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

3.  Determination of the new fluoroquinolone fleroxacin and its N-demethyl and N-oxide metabolites in plasma and urine by high-performance liquid chromatography with fluorescence detection.

Authors:  P Heizmann; D Dell; H Eggers; R Gora
Journal:  J Chromatogr       Date:  1990-04-27

4.  Single and multiple dose pharmacokinetics of fleroxacin.

Authors:  E Weidekamm; R Portmann; C Partos; D Dell
Journal:  J Antimicrob Chemother       Date:  1988-10       Impact factor: 5.790

5.  Comparative oral pharmacokinetics of fleroxacin and pefloxacin.

Authors:  I De Lepeleire; A Van Hecken; R Verbesselt; T B Tjandra-Maga; P J De Schepper
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

6.  Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.

Authors:  F Sorgel; R Metz; K Naber; R Seelmann; P Muth
Journal:  J Antimicrob Chemother       Date:  1988-10       Impact factor: 5.790

7.  Metabolism of fleroxacin in man.

Authors:  F Sörgel; R Seelmann; K Naber; R Metz; P Muth
Journal:  J Antimicrob Chemother       Date:  1988-10       Impact factor: 5.790

8.  The penetration of fleroxacin into bronchial mucosa.

Authors:  R Wise; D Honeybourne; J M Andrews; J P Ashby
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

9.  Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.

Authors:  M Nakashima; M Kanamaru; T Uematsu; A Takiguchi; A Mizuno; T Itaya; F Kawahara; T Ooie; S Saito; H Uchida
Journal:  J Antimicrob Chemother       Date:  1988-10       Impact factor: 5.790

10.  Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin.

Authors:  R Paganoni; C Herzog; A Braunsteiner; P Hohl
Journal:  J Antimicrob Chemother       Date:  1988-10       Impact factor: 5.790

View more
  3 in total

Review 1.  How important are gender differences in pharmacokinetics?

Authors:  Bernd Meibohm; Ingrid Beierle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Decreased maximal aerobic capacity in pediatric chronic kidney disease.

Authors:  Donald J Weaver; Thomas R Kimball; Timothy Knilans; Wayne Mays; Sandra K Knecht; Yvette M Gerdes; Sandy Witt; Betty J Glascock; Janis Kartal; Philip Khoury; Mark M Mitsnefes
Journal:  J Am Soc Nephrol       Date:  2008-01-09       Impact factor: 10.121

Review 3.  The influence of sex on pharmacokinetics.

Authors:  Janice B Schwartz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 5.577

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.